Key Points:
The catalyst: Midjourney’s new medical arm unveiled a 60-second full-body “Ultrasonic CT” scanner that runs on Butterfly Network’s ultrasound-on-chip, rather than relying on Midjourney’s own proprietary hardware.
Butterfly Network (BFLY): the sensor inside the scanner, and increasingly the licensor of the category.
Hyperfine (HYPR): the other imaging company from the same founder, with an FDA-cleared portable AI MRI.
Plus: Three more AI healthcare small-cap stocks and a special extra-credit section on longevity small-caps!
If you follow tech and AI news, this article may seem a tad late. After all, Midjourney announced its new Midjourney Medical segment, centered around the Ultrasonic CT system, about two weeks ago.
The truth is that I wanted to watch the range of reactions to the launch, including reactions from the medical community segments that Midjourney seems to be angling to replace.
To that end, the subsequent weeks have been heavy on the hype and lighter on the details, with the image of a person lowered into a tank of water while half a million tiny transducers map their insides doing most of the work for Midjourney’s press cycle.
One thing’s been made clear, though: strip away the spa lighting and the load-bearing fact is unglamorous, i.e. that the scanner is not Midjourney’s invention. The company that spent three years generating pictures licensed someone else’s hardware to generate this one.
The sensor doing the imaging belongs to a public small-cap, and the launch matters less as a Midjourney story than as a signal about where that small-cap now sits and what it means for the world of AI healthcare small-caps moving forward.
Midjourney Medical says its Ultrasonic CT system will complete a full-body scan in about 60 seconds using sound and water instead of radiation or magnets, and that the current prototype is built on Butterfly Network’s ultrasound-on-chip.
And that’s the rub.
Butterfly is no longer only selling handheld probes; it’s licensing its sensor into other companies’ devices, the way a chip designer licenses a core. Once a component becomes the thing everyone builds on, the vendor stops being a device company and starts being infrastructure.
In many ways, this is reflective of much of the way technical small-caps are taking center stage, in that innovative companies are increasingly relied upon as the engine for a larger, more expansive company that would rather pay a licensing or acquisition fee than lose the race by developing something in-house. We’re seeing it in small-cap space stocks, small-cap defense stocks, and now in AI healthcare small-caps.
Top Small-Cap AI Healthcare Stock: Butterfly Network $BFLY ( ▼ 3.15% )
Butterfly makes the ultrasound-on-chip that turns a semiconductor into a whole-body imaging probe, and it is the direct beneficiary of the Midjourney launch, with shares jumping roughly a third on the news and up 100% YTD.
The number that matters more than the pop is the model shift: through its Butterfly Embedded licensing program, the company now supplies its sensor to third parties building their own products, Midjourney’s scanner among them. That is a higher-margin, more defensible position than selling probes one clinic at a time and represents a sea change in how Butterfly Network and similar healthcare small-caps may position themselves in the future.
First-quarter revenue grew about 25% to $26.5 million with roughly $138 million in cash. At just over $2B the market cap sits at the very top of the small-cap range, a level it reached only after the Midjourney spike; a month earlier it was closer to $1.5 billion.
What’s the Risk?
Butterfly is still unprofitable, and the Midjourney relationship is a co-development deal on a prototype, not a purchase order for 50,000 machines (yet). If the licensing story stalls, the stock re-rates back to a hardware multiple and the recent pop unwinds as fast as it arrived.
The Sister Bet: Hyperfine $HYPR ( ▼ 2.99% )
If Butterfly is the imaging sensor as platform, Hyperfine is the closest thing to a second draft of the same idea.
It sells the first FDA-cleared, AI-powered portable MRI, the Swoop system, which wheels to a patient’s bedside and runs off a standard wall outlet. The connective detail worth knowing: Hyperfine came out of the same founder and incubator as Butterfly, so this is two attempts at making imaging cheap and portable from a single source.
The market value is about $130M, and the company was just added to the Russell 2000 and 3000. Revenue is small but growing fast, up more than 80% year over year in the first quarter against roughly $20 to $22 million of full-year guidance.
The bull case is simple and so is the bear case: adoption has to outrun the cash burn, and the installed base is still measured in the hundreds of systems.